HFHanako Funakoshi

Hanako Funakoshi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hanako Funakoshi has a total of 49 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Clinical Characteristics of Pediatric Clostridioides difficile Infection at a Children's Hospital

    by Joonho Shin, Kenta Kuruma, Hanako Funakoshi, Meiwa Shibata, Yuho Horikoshi

    Background: The epidemiology and clinical characteristics of pediatric Clostridioides difficile infection (CDI) in Japan have not been well characterized. Unlike in adults, C. difficile colonization is common in children, particularly in those younger than 2 years. This study aimed to characterize pediatric CDI in Japan. Methods: This single‐center retrospective observational study included patients at Tokyo Metropolitan Children's Medical Center between April 2010 and May 2024 in whom toxigenic C. difficile was identified by direct stool toxin immunochromatography, toxin testing of isolates recovered by stool culture, or multiplex PCR detection of toxin A/B gene targets. CDI was defined as laboratory evidence of toxigenic C. difficile with compatible gastrointestinal symptoms. Clinical data, including demographic characteristics, underlying conditions, antimicrobial exposure, treatment, severity, outcomes, and recurrence, were extracted from electronic medical records. Results: Among 262 patients tested, 24 were diagnosed with CDI. Fifteen (62.5%) had negative direct stool toxin tests but toxin‐positive isolates obtained from a stool culture. The median age was 5.5 years (interquartile range: 4–10 years); 58% of the patients were male, 75% had received antimicrobial therapy before CDI onset, and 71% had a history of hospitalization. Twelve patients (50%) received CDI‐directed antimicrobial therapy, and 12 patients (50%) improved without specific treatment. Fifteen patients (63%) met the study criteria for severe CDI, but only one was admitted to the pediatric intensive care unit. No recurrences were observed, and the 30‐day mortality rate was 0%. Conclusion: Pediatric CDI had favorable outcomes, with no deaths or recurrences occurring in the present study.

  • Shortening the perioperative prophylactic antimicrobial duration in pediatric ventriculoperitoneal ( VP ) shunt insertion

    by Ayumi Tada, Satoshi Ihara, Junichi Suwa, Hanako Funakoshi, Yuho Horikoshi

    Background: Perioperative antimicrobial therapy is important to prevent central nervous system (CNS) infections following cerebrospinal fluid (CSF) shunt insertion, but the optimal duration remains unclear. This study aimed to evaluate the incidence of ventriculoperitoneal (VP) shunt‐associated CNS infection before and after the revision of the institutional protocol for discontinuing antimicrobial therapy within 48 h after surgery. Methods: Patients aged 15 years or less who underwent VP shunt insertion at Tokyo Metropolitan Children's Medical Center between April 2014 and November 2021 were enrolled retrospectively. The primary outcome was the incidence of VP shunt‐associated CNS infection at postoperative months 1 and 6 in pre‐ and post‐intervention patient groups. Results: Of the 117 patients screened, 27 were excluded. Of the eligible patients, 39 were in the pre‐intervention group, and 51 were in the post‐intervention group. The incidence of VP shunt‐associated CNS infection at month 1 was 7.7% (3/39) in the pre‐intervention group and 7.8% (4/51) in the post‐intervention group ( p = 0.98), with no significant difference. At month 6, the incidence was 7.7% (3/39) in the pre‐intervention group and 13.7% (7/51) in the post‐intervention group ( p = 0.37), also not significantly different. Conclusions: Reducing the duration of antibiotic prophylaxis for VP shunt insertion to within 48 h did not increase the incidence of VP shunt‐associated CNS infection.

  • Duration of antibiotic therapy for pediatric ventilator‐associated pneumonia

    by Aki Miyashita, Hanako Funakoshi, Meiwa Shibata, Osamu Saito, Keiko Nakamura, Shigeko Miyokawa, Yuho Horikoshi

    Background: Although a seven‐day course of antibiotic therapy for ventilator‐associated pneumonia (VAP) is recommended for adult patients, the optimal duration in children remains unclear. Our study described the management of pediatric VAP by focusing on the treatment and clinical outcomes. Methods: We performed a retrospective cohort study in the Pediatric Intensive Care Unit (PICU) of a tertiary children's hospital. Children under 18 diagnosed with VAP between April 2016 and June 2023 were included. VAP was defined by the Centers for Disease Control and Prevention of the United States criteria. Exclusion criteria included co‐infections or a lack of prior antibiotic therapy. Demographic and microbiological data were collected from medical records. Results: Ninety patients were eligible for enrollment. The median age was 19 months (IQR: 10–69 months) and 44% were girls. The median pediatric index of mortality‐2 score was 4 (IQR: 1.3–8.6). Staphylococcus aureus was the most frequently isolated pathogen (28%), followed by Pseudomonas aeruginosa (22%). The median length of antibiotic therapy was six days (IQR: 6–7 days). Mortality on days 7 and 28 was 1% ( n = 1) and 6% ( n = 5), without VAP‐related deaths. The recurrence rate was 10% ( n = 9). The median ventilation‐free and PICU‐free days at day 28 were 22 and 17, respectively. Conclusion: Most patients received a six to seven‐day course of antibiotic therapy without adverse outcomes. The recurrence rate and the ventilation‐free and PICU‐free days were equivalent to or better than those reported previously for adults.


  • Pediatric Bacillus cereus brain abscesses treated with combination therapy

    by Shota Homma, Hanako Funakoshi, Yuichi Yokokawa, Maya Kono, Yuho Horikoshi

  • Post coronavirus disease 2019 condition in children at a children's hospital in Japan

    by Yuho Horikoshi, Meiwa Shibata, Hanako Funakoshi, Shintaro Baba, Sahoko Miyama

    Background: Acute coronavirus disease 2019 (COVID‐19) is associated with chronic symptoms. These have been termed the “post COVID‐19 condition.” The data on this condition in children are still limited. We therefore aimed to elucidate the characteristics of this post COVID‐19 condition.Methods: Children referred to a long COVID‐19 clinic were included at Tokyo Metropolitan Children's Medical Center between October 2021 and July 2022. Children with another diagnosis and those who failed to meet criteria for post COVID‐19 condition were excluded. Demographic and clinical data were collected retrospectively.Results: Of 33 referrals, nine were excluded, and 24 fulfilled the criteria for post COVID‐19 condition. The median age and percentage of girls were 12.5 (IQR: 11–13) years and 29.2%, respectively. All the patients had mild, acute COVID‐19. Dysgeusia and brain fog was observed more frequently during the Delta and Omicron variant periods, respectively. School absenteeism >4 weeks was observed in 41.6% of the patients. Common symptoms included malaise, headache, dysgeusia, and dysosmia. The median duration of post COVID‐19 condition was 4.5 (IQR: 2.8–5.2) months. Pain management and counseling using the pacing approach were the most commonly offered treatments. Symptom resolution and improvement was observed in 29.2% and 54.2% of the patients, respectively.Conclusions: One third of the patients referred for long COVID did not fit the definition of the post COVID‐19 condition. After a median follow up of 4.5 months, the majority of the cases resolved or improved.


  • Infantile primary sternal osteomyelitis due to group B Streptococcus

    by Koichiro Okumura, Shun Sakatani, Hanako Funakoshi, Kazuhiro Uda, Hiroshi Hataya


  • First case of Legionella pneumonia in a female patient with anorexia nervosa

    by Manami Sammori, Hanako Funakoshi, Yoshimitsu Fukai, Naoki Shimizu, Yuho Horikoshi